Prot: KD025-209: A Phase 2, Randomized, Placebo-controlled, Double-blind, Open-label Extension Multicenter Study to Evaluate the Efficacy and Safety of KD025 in Subjects with Diffuse Cutaneous Systemic Sclerosis

Project: Research project

StatusActive
Effective start/end date10/11/1910/11/22

Funding

  • Kadmon Corporation, LLC (Prot: KD025-209)